oxycontin 10
rafa laboratories ltd - oxycodone hydrochloride - tablets controlled release - oxycodone hydrochloride 10 mg - oxycodone - oxycodone - for the relief of moderate to severe chronic pain.
oxycontin 80
rafa laboratories ltd - oxycodone hydrochloride - tablets controlled release - oxycodone hydrochloride 80 mg - oxycodone - oxycodone - for the relief of moderate to severe chronic pain.
oxycontin 40
rafa laboratories ltd - oxycodone hydrochloride - tablets controlled release - oxycodone hydrochloride 40 mg - oxycodone - oxycodone - for the relief of moderate to severe chronic pain.
ondansetron dr reddy's ondansetron (as hydrochloride dihydrate) 4 mg film-coated tablet blister pack
dr reddys laboratories australia pty ltd - ondansetron hydrochloride dihydrate, quantity: 5 mg (equivalent: ondansetron, qty 4 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; magnesium stearate; pregelatinised maize starch; sodium starch glycollate; colloidal anhydrous silica; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 400 - prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy.
ondansetron dr reddy's ondansetron (as hydrochloride dihydrate) 8 mg film-coated tablet blister pack
dr reddys laboratories australia pty ltd - ondansetron hydrochloride dihydrate, quantity: 10 mg (equivalent: ondansetron, qty 8 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; pregelatinised maize starch; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; sodium starch glycollate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 400 - prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy.
imatinib dr.reddy's imatinib (as mesilate) 400mg capsule blister pack
dr reddys laboratories australia pty ltd - imatinib mesilate, quantity: 477.88 mg (equivalent: imatinib, qty 400 mg) - capsule, hard - excipient ingredients: crospovidone; purified water; gelatin; iron oxide yellow; sodium lauryl sulfate; titanium dioxide; sodium stearylfumarate; iron oxide black; iron oxide red; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; ethanol absolute; ammonia - indicated for the: ,? treatment of patients with chronic myeloid leukaemia (cml) ,? treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy,? treatment of adult patients with relapsed or refractory ph+ all as monotherapy ,? treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements, where conventional therapies have failed ,? treatment of adult patients with aggressive systemic mastocytosis (asm), where conventional therapies have failed ,? treatment of adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) ,? adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (dfsp). ? treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist) ? adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of kit (cd117)-positive primary gist (see dosage and administration and clinical trials)
imatinib dr.reddy's imatinib (as mesilate) 50mg capsule blister pack
dr reddys laboratories australia pty ltd - imatinib mesilate, quantity: 59.735 mg (equivalent: imatinib, qty 50 mg) - capsule, hard - excipient ingredients: purified water; titanium dioxide; sodium lauryl sulfate; iron oxide yellow; sodium stearylfumarate; gelatin; crospovidone; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; iron oxide red; ethanol absolute; ammonia - indicated for the: ,? treatment of patients with chronic myeloid leukaemia (cml) ,? treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy,? treatment of adult patients with relapsed or refractory ph+ all as monotherapy ,? treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements, where conventional therapies have failed ,? treatment of adult patients with aggressive systemic mastocytosis (asm), where conventional therapies have failed ,? treatment of adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) ,? adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (dfsp). ? treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist) ? adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of kit (cd117)-positive primary gist (see dosage and administration and clinical trials)
imatinib dr.reddy's imatinib (as mesilate) 100mg capsule blister pack
dr reddys laboratories australia pty ltd - imatinib mesilate, quantity: 119.47 mg (equivalent: imatinib, qty 100 mg) - capsule, hard - excipient ingredients: sodium stearylfumarate; sodium lauryl sulfate; gelatin; iron oxide yellow; crospovidone; titanium dioxide; purified water; iron oxide red; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; ethanol absolute; ammonia - indicated for the: ,? treatment of patients with chronic myeloid leukaemia (cml) ,? treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy,? treatment of adult patients with relapsed or refractory ph+ all as monotherapy ,? treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements, where conventional therapies have failed ,? treatment of adult patients with aggressive systemic mastocytosis (asm), where conventional therapies have failed ,? treatment of adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) ,? adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (dfsp). ? treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist) ? adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of kit (cd117)-positive primary gist (see dosage and administration and clinical trials)
ondansetron odt dr reddy's ondansetron 8 mg orally disintegrating tablet blister pack
dr reddys laboratories australia pty ltd - ondansetron, quantity: 8 mg - tablet, orally disintegrating - excipient ingredients: magnesium stearate; microcrystalline cellulose; guar gum; crospovidone; sodium lauryl sulfate; colloidal anhydrous silica; mannitol; aspartame; pregelatinised maize starch; flavour - prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy.
ondansetron odt dr reddy's ondansetron 4 mg orally disintegrating tablet blister pack
dr reddys laboratories australia pty ltd - ondansetron, quantity: 4 mg - tablet, orally disintegrating - excipient ingredients: crospovidone; magnesium stearate; sodium lauryl sulfate; mannitol; colloidal anhydrous silica; pregelatinised maize starch; microcrystalline cellulose; aspartame; guar gum; flavour - prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy.